Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Trading Statement

19 Jul 2012 07:00

RNS Number : 9983H
Biome Technologies PLC
19 July 2012
 



19 July 2012

 

Biome Technologies plc ("Biome", "the Company" or "the Group")

 

Interim Trading Statement

 

 

Biome Technologies plc, the bioplastics and RF technology business, is pleased to announce a trading update, ahead of its Interim Results for the six-month period ended 30 June 2012, which are expected to be announced on 3 September 2012.

 

Total Group revenues achieved in the first half of 2012 were £7.5m, down 28% on the same period in 2011. In the Trading Update of 31 May, it was stated that sales within the Bioplastics Division for April and May were markedly below our expectations following legislative changes in Italy and wider disruption to the supply and demand balance in Europe. This is reflected in the second quarter, with Group revenues of £2.9m (Q2 2011: £4.9m), 38% below the revenues of £4.6m achieved in the first quarter.

 

The Bioplastics Division saw revenues drop from £4.3m in Q1 to £2.2m in the second quarter (Q2 2011: £3.9m). Within this, Biotec was most adversely affected with revenues down 58% from £3.0m in Q1 to £1.2m in the second quarter (Q2 2011: £1.8m) as third-party sales were depressed due to the previously reported demand changes in southern Europe. In Biome Bioplastics, revenues were down a more modest 26% to £1.0m in the second quarter compared to £1.3m in Q1 (Q2 2011: £2.2m) with some evidence that the broader application base and geographic diversity is providing greater resilience to the current turbulence in the market.

 

The Stanelco RF Technologies Division continues to perform as expected with revenues of £0.7m in Q2, up 95% compared to the first quarter (Q2 2011: £0.9m). The pipeline for fibre optic furnace systems and associated spares continues to grow; orders for nine units to the value of £1.2m have been received and are under build for the second half, with further orders pending. Diversification into new industrial markets continues and the Durapipe UK project is progressing well with the first prototype unit expected to be delivered shortly.

 

The Group's cash position at 30 June 2012 was £1.1m (30 April 2012: £1.5m). Following the period end, the Group announced that Biotec had entered into a €1.5m loan agreement with Sparkasse Emmerich and that €255k in repayment and interest had been repaid to Biome under the shareholder agreement. The Group's secured debt facility of up to £2m with Fortis Commercial Finance remains available but is currently not utilised.

 

The Board continues to believe that these market developments constitute a pause in a fast developing market and that the drivers of requirements for biodegradable and bio-based materials will grow with time.

 

With respect to the patent litigation, updated on 12 July, the recent positive findings in the Court of Turin in the context of other court findings provide further confidence in the value and potential of the Group's technology Biome is well placed and continues to expedite new product development with a focus on those opportunities likely to yield growth in the shorter term. Actions to reduce costs by around by £0.6m on an annualised basis have now been completed and the benefits will build in the second half. The Group is trading in-line with the Board's revised expectations.

 

-Ends-

 

For further information please contact:

 

Biome Technologies plc

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com Tel: +44 (0) 2380 867 100

 

Daniel Stewart & Company plc

David Hart/Jamie Barklem

www.danielstewart.co.uk Tel: +44 (0) 20 7776 6550

 

First Columbus

Chris Crawford/Kelly Gardiner

www.first-columbus.com Tel: +44 (0) 20 3002 2070

 

FTI Consulting

Oliver Winters/Latika Shah Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFWAFESEEW
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.